Developing novel biologics for autoimmune diseases
Jade’s focus is to develop transformational, disease-modifying therapies targeting autoimmune diseases. The company’s lead candidate, JADE101, is a potentially best-in-class antibody designed to block the cytokine APRIL (A PRoliferation Inducing Ligand) protein. JADE101 is anticipated to enter the clinic in the second half of 2025, with interim biomarker-rich data expected in the first half of 2026. Jade’s pipeline also includes a second development candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development.
|
Program
|
Candidate
|
Discovery
|
IND-Enabling
|
Planned Clinical FIH
|
Planned Interim FIH Data
|
Potential Indications
|
|---|---|---|---|---|---|---|
| MOA: Anti-aprilJADE-001
| JADE101
|
| 2H25
| 1H26
| IgAN
|
|
|
JADE101 is a potential best-in-class monoclonal antibody designed to block the APRIL (A PRoliferation Inducing Ligand) protein, which plays a key role in the development of IgA nephropathy (IgAN), a chronic kidney disease resulting from inflammation and damage that can impair kidney function over time. By targeting the underlying pathogenesis of IgAN, JADE101 is designed to reduce IgA levels, lower protein levels in the urine (a key marker of kidney damage), and preserve long-term kidney function. Learn more |
||||||
| MOA: UndisclosedJADE-002
| JADE201
|
| 1H26
| Multiple systemic AI diseases
|
||
|
|
||||||
| MOA: UndisclosedJADE-003
|
| 1H27
| Undisclosed
|
|||
|
|
||||||
JADE101 is a potential best-in-class monoclonal antibody designed to block the APRIL (A PRoliferation Inducing Ligand) protein, which plays a key role in the development of IgA nephropathy (IgAN), a chronic kidney disease resulting from inflammation and damage that can impair kidney function over time. By targeting the underlying pathogenesis of IgAN, JADE101 is designed to reduce IgA levels, lower protein levels in the urine (a key marker of kidney damage), and preserve long-term kidney function.
Learn more